Canaccord Genuity initiated coverage on Annovis Bio with a new price target
$ANVS
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | Buy → Hold | D. Boral Capital | |
| 10/25/2024 | $25.00 | Hold → Buy | Maxim Group |
| 12/29/2023 | $36.00 | Buy | Canaccord Genuity |
| 7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
10-Q - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
424B5 - Annovis Bio, Inc. (0001477845) (Filer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population. "We are pleased with such proactive engagement with the FD
Buntanetap significantly improves cognition in all Parkinson's patients, with those exhibiting Alzheimer's co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap treatment Findings support buntanetap's potential to address cognitive decline in Parkinson's disease, show disease-modifying efficacy, and inform future clinical development MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al
D. Boral Capital downgraded Annovis Bio from Buy to Hold
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to
SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)
SC 13G - Annovis Bio, Inc. (0001477845) (Subject)